Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.

Murray SM. et al, (2022), Nature reviews. Immunology, 1 - 13

A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.

Sampson O. et al, (2022), J Immunol Methods, 504

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nature communications, 13

Infection of liver hepatocytes with SARS-CoV-2.

Barnes E., (2022), Nature metabolism, 4, 301 - 302

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

Townsend A. et al, (2021), Nature Communications, 12

Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study

Wang T. et al, (2021), BMC Infectious Diseases, 21

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses

Ogbe A. et al, (2021), Nature Communications, 12

Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019

Wang T. et al, (2021), Hepatology Communications, 5, 1586 - 1604

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy

Smith DA. et al, (2021), Journal of Viral Hepatitis, 28, 1256 - 1264

Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations

Mokaya J. et al, (2021), Journal of Viral Hepatitis, 28, 1110 - 1120

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485

Therapeutic vaccination for treatment of chronic hepatitis B.

Cargill T. and Barnes E., (2021), Clinical and experimental immunology, 205, 106 - 118

Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.

Webb GJ. et al, (2021), Journal of hepatology, 75, 226 - 228

High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study

Flower B. et al, (2021), Open Forum Infectious Diseases, 8

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

SARS-CoV-2 infection in patients with autoimmune hepatitis.

Marjot T. et al, (2021), Journal of hepatology, 74, 1335 - 1343

The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization.

Innes H. et al, (2021), Gastroenterology, 160, 2599 - 2601.e2

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?

In this section